GL1X · GenesisL1 explorer

Research workbench

Crystal structure of braf kinase domain bound to belvarafenib

Analyse Crystal structure of braf kinase domain bound to belvarafenib in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6XFP
Type
protein
Length
272 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
SERINE/THREONINE-protein kinase B-RAF
UniProt
H7C560
Ligands
V1Y, CL
Pockets
2 · best druggability 0.76

Structure

x-ray diffraction · 1 distinct chain · 39% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ASERINE/THREONINE-protein kinase B-RAFprotein27239% helix, 18% strandH7C560

Ligands and binding sites

  • V1Y · 4-amino-N-{1-[(3-chloro-2-fluorophenyl)amino]-6-methylisoquinolin-5-yl}thieno[3,2-d]pyrimidine-7-carboxamide · ligand · chains A
  • CL · Chloride ion · ion · 6 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15130.760.8354V1Y, CL
2580.350.7813CL

Compared structures

  • 6XFP · Crystal Structure of BRAF kinase domain bound to Belvarafenib · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.